GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1

A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants

A Randomised Study to Investigate Steady State Semaglutide Exposure of a New Formulation of Oral Semaglutide in Healthy Participants

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

Oral · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

264

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 23-34.9•Healthy volunteers

Primary endpoint

•AUC0-24h,semaglutide,SS

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05784402

Org study IDNN9924-4891

Secondary IDU1111-1279-6289World Health Organization (WHO)

Timeline

Milestones

Study start2023-03-16actual

Study first posted2023-03-24actual

Primary completion2024-02-23actual

Study completion2024-03-29actual

Last update posted2025-12-02actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years

Maximum age64 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Body mass index (BMI) between 23.0 and 34.9 kilograms per meter square (kg/m^2) (both inclusive) at screening

•Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator

Exclusion criteria

•Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method

•Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol

•Use of prescription medicinal products or non-prescription drugs, except highly effective contraceptives, routine vitamins, topical medication not reaching the systemic circulation and occasional use of paracetamol (acetaminophen) and ibuprofen within 14 days before screening

•Presence of clinically significant gastrointestinal disorders potentially affecting absorption of drugs, as judged by the investigator

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

3 endpoints

Primary/protocol endpoint

AUC0-24h,semaglutide,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady state

Time frame:From 0 to 24 hours after dosing on days 77, 112 and 147

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Cmax,0-24h.semaglutide,SS; maximum observed plasma concentration of semaglutide at steady state

Time frame:From 0 to 24 hours after dosing on days 77, 112 and 147

Cmax

concentration, descriptive

Secondary/protocol endpoint

tmax,0-24h,semaglutide,SS; Time to maximum semaglutide plasma concentration at steady state

Time frame:From 0 to 24 hours after dosing on days 77, 112 and 147

Tmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.